Business
Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is expected to close in the first h
About this update from Swedish Orphan Biovitrum Ab
[{"type":"text","content":"STOCKHOLM, Dec. 15, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (STO: SOBI) recently announced that it has entered into an acquisition agreement with Arthrosi Therapeutics, Inc., which was invested in and incubated by Viva Biotech Holdings. Under the terms of the agreement, Sobi will pay up to US$1.5 billion in total transaction value, including an upfront payment at closing of US$950 million, subject to customary adjustments, and contingent consideration of up to US$550 million. The transaction is expected to close in the first half of 2026.","length":558,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/Viva Biotech)","displaySize":"","headline":null,"caption":"(PRNewsfoto/Viva Biotech)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":143,"url":"https://media.zenfs.com/en/prnewswire.com/1bdaf7b965393aced1e132cf142d2b89"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/t7dCRcB_pWclPGY7dRP0Yw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTI1MjtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1bdaf7b965393aced1e132cf142d2b89","width":400,"height":143}},"href":"https://mma.prnewswire.com/media/2784195/Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Viva Biotech expects that the Merger will result in an aggregate gain of approximately US$40.0 million. The exact amount will depend on the fulfilment of regulatory and performance milestones. In addition, Arthrosi has also entered into new statement of work (SOW) with the Viva Biotech's CDMO business unit (Langhua Pharmaceutical) for the supply of active pharmaceutical ingredient, and the Group expects to continue its business cooperation with Arthrosi.","length":462,"tagName":"p"},{"type":"text","content":"Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels, flares, and dissolve tophi in gout and tophaceous gout patients. The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882), an investigational next-generation, once-daily oral URAT1 inhibitor currently being evaluated in two fully recruited global Phase 3 clinical studies for the potential management of progressive and tophaceous gout and expected to read out in 2026. Pozdeutinurad ...